UNSPSC 51132207: Acetaminophen/aspirin/caffeine/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132207 Acetaminophen/aspirin/caffeine/salicylamide, a Commodity code, shows limited recent activity directly aligned with its nominal scope. The three recent state and local opportunities posted under this code reflect pharmaceutical procurement more broadly—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with OTC products—rather than procurement specifically targeting the combination analgesic and stimulant compound the code names. State and local governments buying under this code are primarily health departments, state health and human services agencies, and cooperative purchasing consortia that aggregate demand across multiple jurisdictions. The work involves sourcing pharmaceuticals for community health initiatives, employee health plans, and statewide pharmacy benefit programs, with vendors required to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act requirements, and substantial insurance coverage mandates.

Solicitation activity appears concentrated in Florida and Texas, with cooperative purchasing spanning Minnesota and Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription program capabilities, and the Minnesota Multistate Cooperative Purchasing Alliance's S1070000015802 RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers. The MMCAP cooperative vehicle indicates the code's activity often spans multiple states and local governments through shared procurement instruments rather than individual jurisdiction solicitations, with contract terms typically two years and evaluation weighted heavily on price competitiveness.